EQUANIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EQUANIL (EQUANIL).
Gamma-aminobutyric acid (GABA) receptor positive allosteric modulator; increases frequency of chloride channel opening, potentiating inhibitory neurotransmission.
| Metabolism | Primarily hepatic via glucuronidation; minor CYP2C19 involvement; metabolite: meprobamate (active). |
| Excretion | Primarily renal excretion of conjugated metabolites (inactive); approximately 90% of a dose is excreted in urine, with less than 10% in feces. Less than 5% is excreted unchanged. |
| Half-life | Terminal elimination half-life is 6-20 hours (mean 10 hours). In hepatic cirrhosis, half-life may be prolonged to 24-36 hours due to impaired clearance. |
| Protein binding | 30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.75-1.0 L/kg. The moderate Vd indicates distribution into total body water and some tissue binding, with minimal accumulation. |
| Bioavailability | Oral: 90-100% (well absorbed from GI tract). |
| Onset of Action | Oral: 1-2 hours (time to peak plasma concentration 2-4 hours). Intravenous: within 5-15 minutes. |
| Duration of Action | Oral: 6-8 hours for anxiolytic effect. Duration may be extended in elderly or liver impairment. |
400 mg orally 3-4 times daily; maximum 2400 mg/day. Alternatively, 200 mg orally 3-4 times daily for mild anxiety.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 50% every 6-8 hours. GFR 10-29 mL/min: 200-400 mg every 8-12 hours. GFR <10 mL/min: 200-400 mg every 12-18 hours. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use; if necessary, 200 mg every 12-24 hours. |
| Pediatric use | Children 6-12 years: 100-200 mg orally 2-3 times daily. Maximum 600 mg/day. Not recommended under 6 years. |
| Geriatric use | Initiate at 200 mg orally 2 times daily; increase slowly. Maximum 800 mg/day. Avoid if possible due to anticholinergic effects and fall risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EQUANIL (EQUANIL).
| Breastfeeding | Excreted into breast milk; M/P ratio approximately 0.1-0.5. Can cause sedation, poor feeding, and weight loss in infants. Avoid use while breastfeeding; if used, monitor infant for drowsiness and feeding issues. |
| Teratogenic Risk | First trimester: Increased risk of cleft lip/palate (OR 1.5-2.0) based on studies; potential for congenital heart defects. Second/third trimester: Risk of neonatal withdrawal syndrome, hypotonia, respiratory depression, and feeding difficulties. Use contraindicated if possible, especially in first trimester. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to meprobamate or any component","Acute intermittent porphyria","Concurrent use with other sedative-hypnotics (relative)","Pregnancy (especially first trimester)"]
| Precautions | ["Risk of dependence and withdrawal reactions upon discontinuation","Potentiation of CNS depressants (e.g., alcohol, opioids)","May impair cognitive and motor function","Use with caution in patients with history of substance abuse","Elderly patients may be more sensitive to sedative effects"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal vital signs, sedation level, and respiratory function. Fetal monitoring (ultrasound) for growth restriction near term. Neonatal assessment for withdrawal symptoms (e.g., irritability, tremors) and respiratory depression after delivery. |
| Fertility Effects | May cause menstrual irregularities and anovulation at high doses. Limited evidence of reversible fertility impairment in females; no significant impact on male fertility reported. |